Inthera Bioscience raises CHF 10.5 million in series A financing round

20 June 2017

VISCHER advises Inthera Bioscience AG, a Zurich based biopharmaceutical company, developing first-in-class targeted small molecule therapies for solid tumors.

Inthera Bioscience employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs). The company’s drug discovery programs are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development.

The VISCHER team includes Christian Wyss (Partner), Dania Salvisberg-Schneider (Senior Associate), both Corporate and Nadia Tarolli (Partner), Tax.